Status:
COMPLETED
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care
Lead Sponsor:
Janssen Pharmaceutica N.V., Belgium
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this registry is to document the characteristics and management of patients with metastatic castrate resistant prostate cancer (mCRPC) in routine clinical practice, independent of treat...
Detailed Description
This is a non-interventional, multicenter, prospective registry of patients with a confirmed diagnosis of adenocarcinoma of the prostate presenting with mCRPC, based on documented metastatic prostate ...
Eligibility Criteria
Inclusion
- Patients with a histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate Patients with documented metastatic prostate cancer Patients with documented castration resistance Patients either: Initiating a new systemic mCRPC treatment; or considered to be in surveillance according to clinical practice Sign (or their legally-acceptable representatives must sign) a participation agreement or informed consent form (ICF), per local regulations.
Exclusion
- Any patient who is withdrawn from the registry for any reason may not re-enter the registry
Key Trial Info
Start Date :
June 14 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 21 2018
Estimated Enrollment :
3050 Patients enrolled
Trial Details
Trial ID
NCT02236637
Start Date
June 14 2013
End Date
November 21 2018
Last Update
November 12 2019
Active Locations (146)
Enter a location and click search to find clinical trials sorted by distance.
1
Salzburg, Austria
2
Vienna, Austria
3
Aalst, Belgium
4
Antwerp, Belgium